A Phase 2 interventional study of Midostaurin and Placebo in Acute Myeloid Leukemia, sponsored by Novartis Pharmaceuticals. Completed at 34 sites in 6 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-03-20.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies testing midostaurin in Leukemia, Myeloid, Acute — 2 open to participants now, 4 under way, none of them phase 3. midostaurin · Leukemia, Myeloid, Acute.
Among the 27 studies testing midostaurin in Leukemia, Myeloid, Acute, this one is the 10th largest by enrollment, is one of 6 that started in 2018, is one of 11 in phase 2, and was the 19th registered.
3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 813 are open to participants now.
Browse Leukemia, Myeloid, Acute studies →2 of the 27 studies testing midostaurin in Leukemia, Myeloid, Acute are open now, in 2 countries. Recruiting first, the newest first:
Richard Stone, MD · Sites in United States
Ages 18–75
Technische Universität Dresden · Sites in Germany
Ages 18–75
By country, each count listing its studies:
midostaurin: first FDA approval 2017 (RYDAPT), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →
Of the 621 Leukemia, Myeloid, Acute studies recruiting now, 361 (58%) set no upper age limit and 220 (35%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 17 · Phase 3 4
First in 2002; this study’s year is marked. 6 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 67 is above the median of 40 across 3,007 interventional studies indexed under Leukemia, Myeloid, Acute.
Median enrollment 34 across the 27 interventional studies. Of the 21 that completed or were terminated, 12 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 27 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,721 studies on the registry; 222 are open to participants now.
Of its 586 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
40 studies in Leukemia, Myeloid, Acute by Novartis: none open now, 3 under way, none of them phase 3. Of 31 finished, 20 (65%) have results posted.
Among the 40 studies in Leukemia, Myeloid, Acute by Novartis, this one is the 18th largest by enrollment of the 36 interventional ones that give a count, is one of 3 that started in 2018, is one of 12 in phase 2, and was the 27th registered.
Novartis’s Leukemia, Myeloid, Acute studies by the year they started, since 1999.
3 of the studies testing midostaurin in Leukemia, Myeloid, Acute that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT00819546Richard Stone, MDRAD001 in Combination With PKC412 in Patients With Relapsed, Refractory or Poor Prognosis AML or MDS | 2026-12 |
| NCT06313437Richard Stone, MDRevumenib in Combination With 7+3 + Midostaurin in AML | 2027-03-02 |
| NCT04385290Technische Universität DresdenCombination of Midostaurin and Gemtuzumab Ozogamicin in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC) | 2027-04 |
Add all 3 to your calendar (.ics) → With an account.
Among the 27 studies testing midostaurin in Leukemia, Myeloid, Acute, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 40 in Leukemia, Myeloid, Acute:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study evaluated the efficacy and safety of midostaurin in combination with daunorubicin/cytarabine induction, high dose cytarabine consolidation and midostaurin single agent continuation therapy in newly diagnosed patients with FLT3-mutated acute myeloid leukemia (AML).
This was a Phase II, multi-center trial consisting of two parts; Part 1: an open label, safety evaluation part in Japan only (minimum of three evaluable subjects) and Part 2: a double-blind, randomized, placebo-controlled part (60 subjects). Part 1 in Japan and Part 2 outside Japan were initiated simultaneously. Part 1 was conducted to evaluate the safety and tolerability of midostaurin in combination with daunorubicin/cytarabine induction and high-dose cytarabine consolidation in Japanese subjects and was a pre-requisite before allowing participation of Japan in Part 2. Data from Part 1 was reviewed by an Independent safety Committee (ISC) designated by the Sponsor. The ISC reviewed all available safety data in subjects from Japan up to the time of the safety review data cut-off date (6-Sep-2018). A meeting with the ISC was held on 25-Sep-2018: based on safety evaluation in three evaluable subjects, the ISC members recommended to start Part 2 in Japan.
Part 2 of the study included screening phase, treatment phase composed of up to 18 cycles of midostaurin/placebo treatment in combination with chemotherapy (daunorubicin and cytarabine) during induction and consolidation and alone during continuation and 30 days safety follow up from last dose of study treatment (daunorubicin or cytarabine or midostaurin/placebo); and follow up phase for continued remission and survival follow-up (until 36 months after Day 1 of the last subject). Subjects who provided written informed consent were screened for eligibility during the period up to 7 days immediately prior to starting chemotherapy (Day 1). The subject was randomized at Day 8 to receive either midostaurin or placebo only if FLT3 status was mutated. Treatment phase included induction, consolidation and continuation therapies.
Induction therapy: All screened subjects started induction therapy with chemotherapy from Day 1 to Day 7, while the FLT3 mutation status was being determined. Subjects who achieved CR already with induction Cycle 1 went directly to consolidation therapy without a second cycle of induction therapy. Subjects who did not achieve CR with one cycle of induction received a second induction cycle with same treatment as in Cycle 1. Subjects who did not achieve CR after induction 2 discontinued the study treatment and were followed in safety follow up and survival follow-up.
Consolidation therapy: Subjects who achieved a CR after 1 or 2 cycles of induction received consolidation therapy with 3 cycles of high-dose cytarabine for the Japan Adult Leukemia Study Group (JALSG) regimen and 4 cycles of high-dose cytarabine as tolerated for the Randomized AML Trial In FLT3+ subjects \<60 Years old (RATIFY) regimen. Subjects received midostaurin/placebo, orally twice a day, on Days 8 to 21 of each cycle. Each consolidation cycle began within two weeks following hematopoietic recovery (ANC ≥ 1.0 x 109/L, platelet count ≥ 100 x 109/L) but no sooner than four weeks from the beginning of the previous cycle.
Continuation therapy: After hematopoietic recovery (ANC ≥ 1.0 x 109/L, platelet count ≥ 100 x 109/L) following the final cycle of consolidation but no sooner than 14 days after the last dose of midostaurin/placebo during the last consolidation cycle, subjects who maintained a CR received up to 12 cycles (28 days/cycle) of continuous therapy with midostaurin or placebo twice a day. Safety was assessed in this treatment phase for each subject until 30 days after the end of treatment (EOT) and included routine safety monitoring.
The follow-up phases included post treatment follow-up and survival follow-up. During post-treatment follow-up, all subjects continued to be assessed for relapse i.e. every 2 months during years 1 and 2, every 3 months on year 3 and 4 and then yearly and at time of relapse until relapse, withdrawal of consent, death, loss to follow up, or end of study, whichever was earlier following the end of study treatment for any reason other than persistent AML. Subjects who discontinued study treatment due to persistent AML or relapse and the post treatment follow-up phase due to relapse entered a survival follow-up period during which survival was recorded every 3 months. Survival information was obtained by clinical visits or telephone calls or other means until death, withdrawal of consent, lost to follow-up or end of study, whichever was earlier.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients must meet the following laboratory value criteria that indicate adequate organ function at the screening visit:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients took study drug on day 8-21 during induction and consolidation phase; then on days 1-28 for 12 cycles in the continuation (post consolidation) phase.
Drug: Midostaurin
Patients took placebo on day 8-21 during induction and consolidation phase; then on days 1-28 for 12 cycles in the continuation (post consolidation) phase.
Drug: Placebo
Midostaurin 50 mg \[two 25 mg capsules\] were administered twice per day by mouth on day 8-21 during induction and consolidation phase; then on days 1-28 for 12 cycles in the continuation (post consolidation) phase.
Also known as: PKC412
Placebo, two capsules, were administered twice per day by mouth on day 8-21 during induction and consolidation phase; then on days 1-28 for 12 cycles in the continuation (post consolidation) phase.
Percentage of Safety Events (Part 1, Japan Only)
Percentage of Safety Events, defined as death or serious adverse event leading to treatment discontinuation that occurs on or before Day 21 of the first Consolidation cycle. This was determined by the Independent Safety Committee (ISC) to be definitely or probably related to midostaurin. Percentage was calculated based on the percentage of subjects with safety event out of 3 evaluable subjects in Part 1.
Time frame: up to Day 21 of the first Consolidation cycle; cycle = 28 days
Event Free Survival (EFS) (Part 2 - Randomized, Controlled)
Event Free survival is defined as the time from the date of randomization until an EFS event is observed. An EFS event is defined as a failure to obtain a complete remission (CR) within an induction 2, relapse after CR, or death due to any cause, whichever occurs first. The objective was to evaluate the efficacy based on EFS of midostaurin versus placebo in combination with daunorubicin/cytarabine induction, with high-dose cytarabine consolidation, and with midostaurin single agent continuation therapy in newly diagnosed patients with FLT3-mutated AML.
Time frame: up to 3 years after last patient started treatment
Overall Survival
Overall survival defined as the time from the date of randomization to date of death due to any cause
Time frame: up to 3 years after last patient started treatment
Percentage of Participants With Complete Remission (CR)
Complete Remission is defined as the percentage of participants with a CR according to Chelson Criteria, at various timepoints
Time frame: up to 3 years after last patient started treatment
Percentage of Participants With Cumulative Incidence of Relapse (CIR)
CIR (only for patients who achieved CR after study treatment initiation), is measured from the date of first CR to relapse or death due to AML, whichever occurs first.
Time frame: up to 3 years after last patient started treatment
Pharmakinetics (PK) for Midostaurin: AUClast & AUC0-t
Evaluate AUClast \& AUC0-t PK parameters for midostaurin. AUClast: The AUC from time zero to the last measurable concentration sampling time (Tlast) (mass x time x volume-1) AUC0-t: The area under the curve (AUC) from time zero to a measurable concentration sampling time (t) (mass x time x volume-1).
Time frame: Induction Phase: Pre-dose and 1, 3, 6 and 12 hours post dose in Cycle 1 Day 8
Pharmakinetics (PK) for Midostaurin: Cmax
Evaluate Cmax parameter for midostaurin. Cmax: The maximum (peak) observed plasma drug concentration after the first dose administration of midostaurin (mass x volume-1).
Time frame: Induction Phase: Pre-dose and 1, 3, 6 and 12 hours post dose in Cycle 1 Day 8
Metabolite CGP52421: PK Parameters AUClast, AUC0-t
Evaluate the pharmacokinetic of major metabolite of midostaurin CGP52421. AUClast: The AUC from time zero to the last measurable concentration sampling time (Tlast) (mass x time x volume-1) AUC0-t: The area under the curve (AUC) from time zero to a measurable concentration sampling time (t) (mass x time x volume-1).
Time frame: Induction Phase: Cycle 1 Day 8
Metabolite CGP52421: PK Parameter Cmax
Evaluate the pharmacokinetic of major metabolite of midostaurin CGP52421: Cmax. Cmax: The maximum (peak) observed plasma drug concentration after the first dose administration of midostaurin (mass x volume-1).
Time frame: Induction Phase: Cycle 1 Day 8
Metabolite CGP62221: PK Parameters: AUClast, AUC0-t
Evaluate the pharmacokinetic of major metabolite of Midostaurin CGP62221 PK parameters AUClast, AUC0-t
Time frame: Induction Phase: Cycle 1 Day 8
Metabolite CGP62221: PK Parameter: Cmax
Evaluate the pharmacokinetic of major metabolite of Midostaurin CGP62221 PK parameter Cmax. Cmax: The maximum (peak) observed plasma drug concentration after the first dose administration of midostaurin (mass x volume-1).
Time frame: Induction Phase: Cycle 1 Day 8
Change From Baseline in Quality of Life (QoL) Per European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30
The EORTC QLQ-C30 is a 30-item questionnaire with multi-item scales and single-item measures, including five functional scales (physical, role, emotional, cognitive, and social), three symptom scales (fatigue, nausea/vomiting, and pain), six single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial impact), and a global health status/QoL scale. Scores range from 0 to 100, with higher scores indicating higher response levels. High functional scale scores denote healthy functioning, high global QoL scores indicate high QoL, and high symptom scores reflect high symptom levels. Scoring follows the EORTC Scoring Manual, reported by absolute change from baseline. EOI = End of Induction; EOCons = End of Consolidation; EOCont = End of Continuation; EOT = End of Treatment.
Time frame: EOI: up to 1.84 months (after 2 cycles); EOCons: up to 5.52 months (after 4 cycles); EOCont: up to 16.56 months (after 12 cycles); EOT: up to 16.56 months maximum, depending on treatment duration; each cycle = 28 days
Quality of Life (QoL) Per Patient Global Impression of Change (PGIC)
The PGIC is a single self-reported item that asks about change in status of subject's overall satisfaction with medication since starting the standalone study. The specific wording of the PGIC is "Directions: Circle the one number that best describes how your overall satisfaction with your medication had changed since starting the study": "Very much improved" =1; "Much improved" =2; "Minimally improved" =3; "No change" =4; "Minimally worse" =5; "Much worse" =6; "Very much worse" =7. PGI-C questions have been widely used to assess the patient perspective of improvement in clinical trials and have shown clinical validity in a variety of indications, including depression, urinary incontinence and adult asthma and the PGIC score determined frequencies and percentages by scheduled timepoint. EOI = End of Induction; EOCons = End of Consolidation; EOCont = End of Continuation; EOT = End of Treatment.
Time frame: EOI: up to 1.84 months (after 2 cycles); EOCons: up to 5.52 months (after 4 cycles); EOCont: up to 16.56 months (after 12 cycles); EOT: up to 16.56 months maximum, depending on treatment duration; each cycle = 28 days
Part 1 of the study enrolled 5 Japan adult subjects with newly diagnosed (ND) FLT3-mutated or non-mutated AML. Part 2 randomized 62 adult subjects with ND FLT3-mutated AML. The efficacy analysis was on the 62 randomized subjects in Part 2. The safety analysis was considered separately on 5 subjects in Part 1 \& 61 out of 62 randomized subjects in Part 2, as 1 subject did not receive randomized treatment (placebo). The PK analysis was on subjects treated with midostaurin in Part 1 or Part 2.
| Milestone | Midostaurin: Part 1 (Japan Only) | Midostaurin: Part 2 | Placebo: Part 2 |
|---|---|---|---|
| Started | 5 | 0 | 0 |
| Completed | 0 | 0 | 0 |
| Not completed | 5 | 0 | 0 |
| Withdrew: Physician decision | 2 | 0 | 0 |
| Withdrew: Disease progression | 1 | 0 | 0 |
| Withdrew: Adverse event | 2 | 0 | 0 |
| Milestone | Midostaurin: Part 1 (Japan Only) | Midostaurin: Part 2 | Placebo: Part 2 |
|---|---|---|---|
| Started | 0 | 30 | 32 |
| Randomized, not treated | 0 | 0 | 1 |
| Completed | 0 | 4 | 4 |
| Not completed | 0 | 26 | 28 |
| Withdrew: Adverse event | 0 | 4 | 6 |
| Withdrew: Death | 0 | 3 | 0 |
| Withdrew: Physician decision | 0 | 10 | 16 |
| Withdrew: Withdrawal by subject | 0 | 2 | 1 |
| Withdrew: Progressive disease | 0 | 7 | 5 |
Percentage of Safety Events, defined as death or serious adverse event leading to treatment discontinuation that occurs on or before Day 21 of the first Consolidation cycle. This was determined by the Independent Safety Committee (ISC) to be definitely or probably related to midostaurin. Percentage was calculated based on the percentage of subjects with safety event out of 3 evaluable subjects in Part 1.
| Participants | Midostaurin: Part 1 (Japan Only) | Midostaurin: Part 2 | Placebo: Part 2 |
|---|---|---|---|
| Experienced at least 1 adverse event (AE) | 5 | — | — |
| Safety events determined by ISC related to midostaurin (n = 3, 0, 0) | 0 | — | — |
Event Free survival is defined as the time from the date of randomization until an EFS event is observed. An EFS event is defined as a failure to obtain a complete remission (CR) within an induction 2, relapse after CR, or death due to any cause, whichever occurs first. The objective was to evaluate the efficacy based on EFS of midostaurin versus placebo in combination with daunorubicin/cytarabine induction, with high-dose cytarabine consolidation, and with midostaurin single agent continuation therapy in newly diagnosed patients with FLT3-mutated AML.
| Months | Midostaurin: Part 2 | Placebo: Part 2 |
|---|---|---|
| Event Free Survival (EFS) (Part 2 - Randomized, Controlled) | 7.6 (3.6 to NA) | NA (8.2 to NA) |
Overall survival defined as the time from the date of randomization to date of death due to any cause
| Months | Midostaurin: Part 2 | Placebo: Part 2 |
|---|---|---|
| Overall Survival | NA (16.8 to NA) | NA (18.8 to NA) |
Complete Remission is defined as the percentage of participants with a CR according to Chelson Criteria, at various timepoints
| Percentage of participants | Midostaurin: Part 2 | Placebo: Part 2 |
|---|---|---|
| Overall CR | 70.0 (50.60 to 85.27) | 78.1 (60.03 to 90.72) |
| Morphologic CR with incomplete platelet count recovery (CRp) | 6.7 (0.86 to 22.07) | 0.0 (0.00 to 10.89) |
| End of Induction cycle 1 (C1) CR | 56.7 (37.43 to 74.54) | 65.6 (46.81 to 81.43) |
| End of Induction C1: Morphologic CRp | 3.3 (0.08 to 17.22) | 0.0 (0.00 to 10.89) |
| End of Induction cycle 2 (C2) CR | 13.3 (3.76 to 30.72) | 9.4 (1.98 to 25.02) |
| End of Induction C2: Morphologic CRp | 3.3 (0.08 to 17.00) | 0.0 (0.00 to 10.89) |
| End of Consolidation CR | 36.7 (19.93 to 56.14) | 43.8 (26.36 to 62.34) |
| End of Consolidation Morphologic CRp | 3.3 (0.08 to 17.22) | 9.4 (1.98 to 25.02) |
| After treatment discontinuation CR | 10.0 (2.11 to 26.53) | 3.1 (0.08 to 16.22) |
| After treatment discontinuation Morphologic CRp | 0.0 (0.00 to 11.57) | 6.3 (0.77 to 20.81) |
CIR (only for patients who achieved CR after study treatment initiation), is measured from the date of first CR to relapse or death due to AML, whichever occurs first.
| Participants | Midostaurin: Part 2 | Placebo: Part 2 |
|---|---|---|
| Percentage of Participants With Cumulative Incidence of Relapse (CIR) | 21 | 25 |
Evaluate AUClast \& AUC0-t PK parameters for midostaurin. AUClast: The AUC from time zero to the last measurable concentration sampling time (Tlast) (mass x time x volume-1) AUC0-t: The area under the curve (AUC) from time zero to a measurable concentration sampling time (t) (mass x time x volume-1).
| ng*hr/mL | Midostaurin: Part 2 |
|---|---|
| AUClast | 17900 ± 53.5 |
| AUC0-t | 19200 ± 49.0 |
Evaluate Cmax parameter for midostaurin. Cmax: The maximum (peak) observed plasma drug concentration after the first dose administration of midostaurin (mass x volume-1).
| ng/mL | Midostaurin: Part 2 |
|---|---|
| Pharmakinetics (PK) for Midostaurin: Cmax | 2420 ± 46.5 |
Evaluate the pharmacokinetic of major metabolite of midostaurin CGP52421. AUClast: The AUC from time zero to the last measurable concentration sampling time (Tlast) (mass x time x volume-1) AUC0-t: The area under the curve (AUC) from time zero to a measurable concentration sampling time (t) (mass x time x volume-1).
| ng*hr/mL | Midostaurin: Part 2 |
|---|---|
| AUClast | 754 ± 116 |
| AUC0-t | 876 ± 92.3 |
Evaluate the pharmacokinetic of major metabolite of midostaurin CGP52421: Cmax. Cmax: The maximum (peak) observed plasma drug concentration after the first dose administration of midostaurin (mass x volume-1).
| ng/mL | Midostaurin: Part 2 |
|---|---|
| Metabolite CGP52421: PK Parameter Cmax | 98.6 ± 83.5 |
Evaluate the pharmacokinetic of major metabolite of Midostaurin CGP62221 PK parameters AUClast, AUC0-t
| ng*hr/mL | Midostaurin: Part 2 |
|---|---|
| AUClast | 1430 ± 223 |
| AUC0-t | 1730 ± 182 |
Evaluate the pharmacokinetic of major metabolite of Midostaurin CGP62221 PK parameter Cmax. Cmax: The maximum (peak) observed plasma drug concentration after the first dose administration of midostaurin (mass x volume-1).
| ng/mL | Midostaurin: Part 2 |
|---|---|
| Metabolite CGP62221: PK Parameter: Cmax | 196 ± 159 |
The EORTC QLQ-C30 is a 30-item questionnaire with multi-item scales and single-item measures, including five functional scales (physical, role, emotional, cognitive, and social), three symptom scales (fatigue, nausea/vomiting, and pain), six single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial impact), and a global health status/QoL scale. Scores range from 0 to 100, with higher scores indicating higher response levels. High functional scale scores denote healthy functioning, high global QoL scores indicate high QoL, and high symptom scores reflect high symptom levels. Scoring follows the EORTC Scoring Manual, reported by absolute change from baseline. EOI = End of Induction; EOCons = End of Consolidation; EOCont = End of Continuation; EOT = End of Treatment.
| scores on a scale | Midostaurin: Part 2 | Placebo: Part 2 |
|---|---|---|
| EOI: Global health status (GHS):GHS | 27.8 ± 31.03 | 0.0 ± 16.67 |
| EOCons: GHS:GHS | 20.8 ± 11.49 | 37.1 ± 24.54 |
| EOCont: GHS:GHS | 28.3 ± 22.52 | 27.8 ± 10.09 |
| EOT:GHS:GHS | 25.5 ± 21.94 | 28.8 ± 23.33 |
The PGIC is a single self-reported item that asks about change in status of subject's overall satisfaction with medication since starting the standalone study. The specific wording of the PGIC is "Directions: Circle the one number that best describes how your overall satisfaction with your medication had changed since starting the study": "Very much improved" =1; "Much improved" =2; "Minimally improved" =3; "No change" =4; "Minimally worse" =5; "Much worse" =6; "Very much worse" =7. PGI-C questions have been widely used to assess the patient perspective of improvement in clinical trials and have shown clinical validity in a variety of indications, including depression, urinary incontinence and adult asthma and the PGIC score determined frequencies and percentages by scheduled timepoint. EOI = End of Induction; EOCons = End of Consolidation; EOCont = End of Continuation; EOT = End of Treatment.
| Participants | Midostaurin: Part 2 | Placebo: Part 2 |
|---|---|---|
| EOI: Very much improved | 1 | 0 |
| EOI: Much improved | 2 | 1 |
| EOI: Minimally improved | 3 | 0 |
| EOI: No change | 1 | 1 |
| EOI: Minimally worse | 0 | 1 |
| EOCons: Very much improved | 1 | 1 |
| EOCons: Much improved | 2 | 3 |
| EOCons: Minimally improved | 2 | 4 |
| EOCons: No change | 1 | 2 |
| EOCons: Minimally worse | 0 | 1 |
| EOCont: Very much improved | 3 | 2 |
| EOCont: Much improved | 0 | 4 |
| EOCont: Minimally improved | 1 | 0 |
| EOCont: No change | 1 | 0 |
| EOT: Very much improved | 5 | 3 |
| EOT: Much improved | 4 | 8 |
| EOT: Minimally improved | 6 | 4 |
| EOT: No change | 3 | 3 |
| EOT: Minimally worse | 0 | 2 |
Pre-treatment deaths were collected from screening visit up to the first day of treatment, for a maximum duration of 21 days. Participants who died during the screening period are considered as screen failures. On-treatment deaths were collected from start of treatment (FPFT) up to 30 days after study drug discontinuation, for a maximum duration of approx. 55 months. Post-treatment survival follow-up deaths were collected after the on-treatment period up to approx. 36 months. Participants who did not die during the on-treatment period and had not stopped study participation at the time of data cut-off (when study was terminated) were censored.
| Participants | Midostaurin: Part 1 (Japan Only) | Midostaurin: Part 2 | Placebo: Part 2 | Other Participants |
|---|---|---|---|---|
| Total Deaths in study | 3 | 10 | 7 | 7 |
| Deaths on-treatment | 1 | 3 | 1 | 0 |
| Post-treatment survival follow-up deaths | 2 | 7 | 6 | 0 |
| Deaths - Not randomized to any treatment but received chemotherapy | 0 | 0 | 0 | 6 |
| Deaths - Randomized to placebo but did not receive drug | 0 | 0 | 0 | 1 |
Collected over Adverse events were collected from first dose of study treatment to 30 days after last dose of study medication (on-treatment), up to approx. 55 months. Deaths were collected in the post-treatment survival follow up from 31 days after last dose of study medication until the end of the study, up to approx. 36 months. These are not considered AEs. Non-serious events are listed at a 4.99% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Midostaurin: Part 1 (Japan Only) (On-treatment) | 1/5 (20%) | 2/5 (40%) | 5/5 (100%) |
| Midostaurin: Part 2 (On-treatment) | 3/30 (10%) | 12/30 (40%) | 30/30 (100%) |
| Placebo Part 2 (On-treatment) | 1/31 (3.2%) | 10/31 (32.3%) | 31/31 (100%) |
| Midostaurin: Part 1 (Japan Only) (Post-treatment Survival Follow-up) | 2/4 (50%) | — | — |
| Midostaurin: Part 2 (Post-treatment Survival Follow-up) | 7/27 (25.9%) | — | — |
| Placebo: Part 2 (Post-treatment Survival Follow-up) | 6/30 (20%) | — | — |
| Other Participants | 7/7 (100%) | — | — |
| Event | Midostaurin: Part 1 (Japan Only) (On-treatment) | Midostaurin: Part 2 (On-treatment) | Placebo Part 2 (On-treatment) | Midostaurin: Part 1 (Japan Only) (Post-treatment Survival Follow-up) | Midostaurin: Part 2 (Post-treatment Survival Follow-up) | Placebo: Part 2 (Post-treatment Survival Follow-up) | Other Participants |
|---|---|---|---|---|---|---|---|
| Febrile neutropeniaBlood and lymphatic system disorders | 1/5 | 2/30 | 1/31 | — | — | — | — |
| Cardiac failure acuteCardiac disorders | 1/5 | 0/30 | 0/31 | — | — | — | — |
| Multiple organ dysfunction syndromeGeneral disorders | 1/5 | 0/30 | 0/31 | — | — | — | — |
| PneumoniaInfections and infestations | 1/5 | 5/30 | 2/31 | — | — | — | — |
| SepsisInfections and infestations | 1/5 | 3/30 | 1/31 | — | — | — | — |
| Septic shockInfections and infestations | 0/5 | 2/30 | 1/31 | — | — | — | — |
| PyrexiaGeneral disorders | 0/5 | 1/30 | 2/31 | — | — | — | — |
| ThrombocytopeniaBlood and lymphatic system disorders | 0/5 | 1/30 | 1/31 | — | — | — | — |
| Cardiac failureCardiac disorders | 0/5 | 1/30 | 0/31 | — | — | — | — |
| Cardio-respiratory arrestCardiac disorders | 0/5 | 1/30 | 0/31 | — | — | — | — |
| Event | Midostaurin: Part 1 (Japan Only) (On-treatment) | Midostaurin: Part 2 (On-treatment) | Placebo Part 2 (On-treatment) | Midostaurin: Part 1 (Japan Only) (Post-treatment Survival Follow-up) | Midostaurin: Part 2 (Post-treatment Survival Follow-up) | Placebo: Part 2 (Post-treatment Survival Follow-up) | Other Participants |
|---|---|---|---|---|---|---|---|
| NauseaGastrointestinal disorders | 5/5 | 17/30 | 17/31 | — | — | — | — |
| Febrile neutropeniaBlood and lymphatic system disorders | 4/5 | 25/30 | 21/31 | — | — | — | — |
| MalaiseGeneral disorders | 4/5 | 3/30 | 2/31 | — | — | — | — |
| PyrexiaGeneral disorders | 4/5 | 13/30 | 19/31 | — | — | — | — |
| DiarrhoeaGastrointestinal disorders | 2/5 | 20/30 | 17/31 | — | — | — | — |
| AnaemiaBlood and lymphatic system disorders | 3/5 | 17/30 | 15/31 | — | — | — | — |
| StomatitisGastrointestinal disorders | 3/5 | 9/30 | 10/31 | — | — | — | — |
| VomitingGastrointestinal disorders | 3/5 | 8/30 | 14/31 | — | — | — | — |
| Decreased appetiteMetabolism and nutrition disorders | 3/5 | 6/30 | 7/31 | — | — | — | — |
| HypoalbuminaemiaMetabolism and nutrition disorders | 3/5 | 2/30 | 1/31 | — | — | — | — |
Full Analysis Set (FAS): The FAS comprised of all subjects to whom study drug (midostaurin/placebo) had been assigned by randomization. Therefore, all Japanese subjects treated during Part 1 were not eligible for the FAS.
| Age, Customized(Participants) | Midostaurin: Part 1 (Japan Only) | Midostaurin: Part 2 | Placebo: Part 2 | Total |
|---|---|---|---|---|
| <60 years | 3 | 27 | 23 | 53 |
| 60 - <65 years | 2 | 2 | 5 | 9 |
| ≥65 years | 0 | 1 | 4 | 5 |
| Sex: Female, Male(Participants) | Midostaurin: Part 1 (Japan Only) | Midostaurin: Part 2 | Placebo: Part 2 | Total |
|---|---|---|---|---|
| Female | 2 | 16 | 17 | 35 |
| Male | 3 | 14 | 15 | 32 |
| Race/Ethnicity, Customized(Participants) | Midostaurin: Part 1 (Japan Only) | Midostaurin: Part 2 | Placebo: Part 2 | Total |
|---|---|---|---|---|
| Japanese | 5 | 12 | 12 | 29 |
| Korean | 0 | 4 | 6 | 10 |
| Chinese | 0 | 3 | 10 | 13 |
| Vietnamese | 0 | 1 | 4 | 5 |
| Missing | 0 | 1 | 0 | 1 |
| White | 0 | 9 | 0 | 9 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Ran from Apr 2018 to primary completion in Nov 2022, 55 months.
Results were first posted in Feb 2025, 2 years 2 months after primary completion.
Of 57 industry-sponsored phase 2 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 55. This study's 55 months is above that.
Counting every sponsor, half of 442 studies reached it within 60 months; a quarter within 38 and three quarters within 104.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Midostaurin